Truncated RASSF7 promotes centrosomal defects and cell death  by Gulsen, Tulay et al.
Developmental Biology 409 (2016) 502–517Contents lists available at ScienceDirectDevelopmental Biologyhttp://d
0012-16
n Corr
E-mjournal homepage: www.elsevier.com/locate/developmentalbiologyTruncated RASSF7 promotes centrosomal defects and cell death
Tulay Gulsen, Irene Hadjicosti, Yueshi Li, Xinyun Zhang, Paul R. Whitley,
Andrew D. Chalmers n
Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, United Kingdoma r t i c l e i n f o
Article history:
Received 6 November 2014
Received in revised form
31 March 2015
Accepted 2 November 2015
Available online 10 November 2015
Keywords:
RASSF7
Centrosome
Mitosis
Oncogene
Xenopus
Cell deathx.doi.org/10.1016/j.ydbio.2015.11.001
06/& 2015 Elsevier Inc. All rights reserved.
esponding author.
ail address: A.Chalmers@bath.ac.uk (A.D. Chala b s t r a c t
RASSF7 protein localises to the centrosome and plays a key role in mitosis. Its expression is also increased
in a range of tumour types. However, little is known about the molecular basis of RASSF7's function and it
is not clear if it acts as an oncogene in the cancers where its levels are elevated. Here, we carry out the
ﬁrst analysis of the domains of rassf7, focusing on which of them are responsible for its localisation to the
centrosome. Constructs were generated to allow the expression of a series of truncated versions of rassf7
and the level of centrosomal localisation shown by each protein quantiﬁed. This analysis was carried out
in Xenopus embryos which are a tractable systemwhere rassf7 localisation can easily be studied. Our data
shows that the coiled-coil domain of rassf7 is required and sufﬁcient to direct its centrosomal localisa-
tion. The RA domain did not appear to have a role in mediating localisation. Surprisingly, removal of the
extreme C-terminus of the protein caused rassf7 to accumulate at the centrosome and drive centrosome
defects, including accumulation of the centrosomal protein γ-tubulin and an ampliﬁcation of the number
of γ-tubulin foci. These effects required the centrosomal localisation mediated by the coiled-coil domain.
Later in development cells expressing this truncated rassf7 protein underwent cell death. Finally, analysis
of a database of tumour sequences identiﬁed a mutation in RASSF7 which would cause a similar
C-terminal truncation of the protein. Based on our data this truncated protein might drive centrosomal
defects and we propose the hypothesis that truncated RASSF7 could act as an oncogene in a small subset
of tumours where it is mutated in this way.
& 2015 Elsevier Inc. All rights reserved.1. Introduction
Mitosis is a spectacular part of the cell cycle and it is over one
hundred years since errors in this process were ﬁrst proposed to
be linked to the origin of cancers (Boveri, 1902). In animal cells
centrosomes play an essential role during mitosis, they act to
nucleate and anchor microtubule minus ends in a process that
requires γ-tubulin (Luders and Stearns, 2007) and provide a plat-
form for a range of mitotic signalling proteins (Basto and Pines,
2007). Defective regulation of centrosomal proteins has been
linked to cancer formation (de Carcer and Malumbres, 2014; Sa-
tinover et al., 2004), making studying their function important to
provide a better understanding of their role in mitosis and cancer
formation.
One protein which localises to the centrosome and has a key
role in regulating mitosis is RASSF7. There are 10 RASSF family
members which can be divided into 2 groups, the classical RASSFs
(RASSF1-6) have a C-terminal Ras Association (RA) domain, while
the N-terminal RASSFs (RASSF7-10) have their RA domains at themers).opposite end of the protein (Sherwood et al., 2008, 2010). Several
of the classical RASSF proteins are tumour suppressors with es-
tablished roles in a range of biological processes, including mi-
crotubule stability, cell cycle control, apoptosis, immune system
regulation and nuclear transport (Richter et al., 2009; Volodko
et al., 2014). In contrast, RASSF7 (discussed below) and the other
N-terminal proteins are much less well studied (Hesson et al.,
2009; Lee et al., 2011; Li et al., 2013; Lock et al., 2010; Underhill-
Day et al., 2011; Wang et al., 2014).
RASSF7 was originally identiﬁed and called HRC1 in a study
which searched for genes that are close to HRAS1 in the genome
(Weitzel et al., 1992). Our laboratory then identiﬁed it in a mi-
croarray screen comparing superﬁcial and deep cells in early Xe-
nopus embryos, where it was initially called carcinoma associated
protein (Chalmers et al., 2006). Rassf7 has broad expression in
early Xenopus embryos, with high levels in neural and epidermal
tissue (Sherwood et al., 2008). Studies of Human cell lines and
mouse embryos also showed it to be expressed in a wide range of
cell and tissue types (Recino et al., 2010). Functional analysis de-
monstrated that rassf7 is required for mitosis in cells from Xenopus
embryos, where morpholino knockdown caused mitotic defects
(Sherwood et al., 2008). In Human cells shRNA knockdown
also caused defects in mitosis, including aberrant microtubule
Fig. 1. GFP-rassf7 truncation series. A series of constructs were produced that allow
expression of truncated versions of rassf7 fused to GFP. GFP-rassf7 (WT), GFP-rassf7
(RAþA), GFP-rassf7 (RAþAþCC), GFP-rassf7 (RA), GFP-rassf7 (AþCCþB), GFP-
rassf7 (CCþB), GFP-rassf7 (AþCC), GFP-rassf7 (CC), GFP-rassf7 (A), GFP-rassf7 (B).
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ora B activity at the kinetochores (Recino et al., 2010). It has also
been shown that RASSF7 negatively regulates pro-apoptotic JNK
signalling by inhibiting the activity of phosphorylated mitogen-
activated protein kinase 7 (MKK 7) (Takahashi et al., 2011), but it is
not currently clear if the stress and mitotic roles are linked. Con-
sistent with its role in mitosis, both human and Xenopus studies
showed that RASSF7 localises to centrosomes. The aforementioned
studies were performed using fusion proteins in Xenopus embryos
and by staining for endogenous RASSF7 in human cell lines (Re-
cino et al., 2010; Sherwood et al., 2008).
In contrast to the loss of expression seen with many classical
RASSF proteins, microarray studies have shown that RASSF7 ex-
pression is up-regulated in pancreatic, islet cell, endometrial,
ovarian cell and thyroid cancers (Friess et al., 2003; Li et al., 2013;
Logsdon et al., 2003; Lowe et al., 2007; Tan et al., 2009) and the
increase in expression may be driven in some of these tumours by
the fact that RASSF7 is up-regulated by hypoxia (Camps et al.,
2008; Liang et al., 2009; Recino et al., 2010). Despite an increase in
expression in many tumours it is not clear whether RASSF7 is
acting as an oncogene and contributing to tumour formation or
whether its increased expression in tumours is simply a con-
sequence of tumour formation. To begin to understand if RASSF7
might act as an oncogene we are working on establishing the
molecular basis for its function.
Here we focus on determining which domains of RASSF7 are
required to localise it to the centrosome. Xenopus embryos were
used as they are a tractable, in vivo, vertebrate model of devel-
opment and disease with good community resources and are well
suited for carrying out studies of protein function (Bartlett and
Weeks, 2008; Conlon et al., 2012). Our data shows that the coiled-
coil domain of rassf7 is sufﬁcient and required for its centrosomal
localisation, whereas the RA domain does not appear to have a role
in the localisation of the protein. Surprisingly, removing the
C-terminal domain of rassf7 resulted in a large increase in levels of
rassf7 at the centrosome. Expressing this truncated construct also
caused centrosomal defects including a striking increase in the
size and number of the foci positive for the centrosomal protein γ-
tubulin. Mutating the coiled-coil abrogated these effects, arguing
they require RASSF to localise at the centrosomes. Cells expressing
this truncated version of rassf7 ultimately underwent cell death
later in development and an increase in embryo death was also
observed. Finally, we analysed sequences of RASSF7 from a large
database of human cancer samples and identiﬁed a mutation
predicted to result in a similar truncation from a renal clear cell
carcinoma. Our data shows that C-terminally truncated rassf7
promotes centrosomal defects and we speculate that RASSF7 could
be oncogenic in a small subset of tumours which harbour such
truncating mutations.2. Materials and methods
2.1. DNA sequences, plasmids and database/bioinformatics analysis
Xenopus RASSF7 pBlueScript SK(-) clone (X1095b08) was pre-
viously cloned into the gateway system to generate an N-terminal
GFP-rassf7 fusion pCS2 construct (Sherwood et al., 2008). A pCS2
GFP construct was also used as previously described (Chalmers
et al., 2005). The sequence of the Xenopus RASSF7 protein was ob-
tained from NCBI: Ras-association domain family 7 [Xenopus laevis]
(ABR21988.1). The Simple Modular Architecture Research Tool
(SMART: http://smart.embl-heidelberg.de/) was used to identify po-
tential protein domains and this informationwas then used to inform
design of the GFP-rassf7 truncation constructs and the coiled coil
mutations which were generated as described below.Mutations in RASSF7 from human cancer samples were iden-
tiﬁed using cBioPortal from the Cancer Genomics website (http://
www.cbioportal.org/public-portal/index.do) which contained data
from 89 cancer genomic studies covering a total of 20,958 tumour
samples (August–Nov 2014). Sequence of the human protein was
obtained from the NCBI (Ras-association domain containing pro-
tein 7 isoform 1 [Homo sapiens]:NP_003466.1) and SMART was
then used to predict the effect of the mutations on the expected
domains produced by human RASSF7 from these cancer samples.
2.2. Primer design and site-directed mutagenesis
The QuickChange site-directed mutagenesis kit (Agilent Tech-
nologies) was used to make plasmids coding for a series of trun-
cated versions of GFP-rassf7 (Fig. 1), by mutating the original GFP-
rassf7 CS2 plasmid. Primers were designed according to the
kit guidelines and PCR was carried out following the protocol
supplied by the manufacturer. Following mutagenesis all con-
structs were sequenced to conﬁrm the mutations were made
correctly.
The following PCR primers were used: GFP-rassf7 (RAþAþCC)
forward: 5′-CTCAGGCAGTGTAACCTCCAATAATTTATCCTTCAGACAG
G-3′ reverse: 5’- CCTGTCTGAAGGATAAATTATTGGAGGTTACACTGC
CTGAG-3′, GFP-rassf7 (RAþA) forward: 5′-GCTTGGAGAAGAGATG
TTTTAGGAGGATGAACTGCAAAGG-3′ reverse: 5’- CCTTTGCAGTT-
CATCCTCCTAAAACATCTCTTCTCCAAGC-3′, GFP-rassf7 (RA) for-
ward: 5′-GAGGCGCACAGGACCATGATTAGCTGAACGTCCATC-3′ re-
verse: 5’- GATGGACGTTCAGCTAATCATGGTCCTGTGCGCCTC-3′,
GFP-rassf7 (AþCCþB) forward: 5′-CTCATTCCTCGTGTTCAA-
TATGAGCTTAGCTGAACGTCCATCCTC-3′ reverse: 5′-GAGGATG-
GACGTTCAGCTAAGCTCATATTGAACACGAGGAATGAG-3′, GFP-rassf7
(CCþB) forward: 5′-CCTCATTCCTCGTGTTCAATTGGGAGGAT-
GAACTGC-3′ reverse: 5′-GCAGTTCATCCTCCCAATTGAACACGAGGA
ATGAGG-3′, GFP-rassf7 (AþCC) forward: 5′-CTCAGGCAGTGTAA
CCTCCAATAATTTATCCTTCAGACAGG-3′ reverse: 5′-CCTGTCTGA
AGGATAAATTATTGGAGGTTACACTGCCTGAG-3′, GFP-rassf7 (CC)
forward: 5′-CCTCATTCCTCGTGTTCAATATGTGGGAGGATGAACTGC
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CACGAGGAATGAGG-3′, GFP-rassf7 (A) forward: 5′-GGAGAAGA-
GATGTTTTGAGAGGATGAACTGCAAAGGGC-3′ reverse: 5′-
GCCCTTTGCAGTTCATCCTCTCAAAACATCTCTTCTCC-3′, GFP-rassf7
(B) forward: 5′-CCTCATTCCTCGTGTTCAATGCCAGGAATCAGGAGC-
3′ reverse: 5′-GCTCCTGATTCCTGGCATTGAACACGAGGAATGAGG-3′.
To add point mutations to the coiled-coil region hydrophobic
residues were identiﬁed and mutations made that would replace
the hydrophobic amino acid with the hydrophilic amino acid
proline. The smart tool was used to select the mutations which
would cause the biggest disruption in the coiled coil and these
were then made using the the QuickChange kit.
The following PCR primers were used for coiled coil mutations:
GFP-rassf7 (RAþAþCC′þB) forward: 5′-GAGGAGTACACCGTGAAA
ATACAGGAGCTCACTGAGCGG-3′ reverse: 3′-CCGCTCAGTGAGCT
CCTGTATTTTCACGGTGTACTCCTC-5’, GFP-rassf7 (RAþAþCC″þB)
forward: 5′-GTTTTGGGAGGATGAACCGCAAAGGGAAAGGGCAG-3′,
reverse: 3′-CTGCCCTTTCCCTTTGCGGTTCATCCTCCCAAAAC-5’, GFP-
rassf7 (RAþAþCC‴þB) forward: 5′-GGAATCAGGAGCCCGACGAA
GTGGACGAAG-3′, reverse: 3′-CTTCGTCCACTTCGTCGGGCTCCTGAT
TCC-5′. All constructs were sequenced to conﬁrm the mutations
were made correctly.
2.3. Embryo fertilisation and cultures
Xenopus laevis eggs were fertilised using standard procedures
(Sive et al., 2000), chemically dejellied in (3% cysteine in 0.1 X
Marc's Modiﬁed Ringer's solution (MMR), pH 7.9) and transferred
to 0.1 X MMR, pH 7.4 (100 mM NaCl, 2 mM KCl, 2 mM CaCl2, 1 mM
MgCl2 and 5 mM HEPES). Embryos were staged according to
Nieuwkoop and Faber (Nieuwkoop and Faber, 1967) or by cell
number. Embryos were cultured in 0.1 X MMR until the required
stage or transferred to injection buffer for microinjection.
2.4. RNA overexpression
The GFP-rassf7 pCS2 plasmid, GFP plasmid and GFP-rassf7
mutant plasmids were used as templates to transcribe mRNA,
using the message machine kit (Ambion, Austin, TX). Xenopus
Embryos were transferred to the injection buffer (1% Ficoll, 0.5 X
MMR) and 9.2 nl of RNA (1:1 dilution) was injected into one cell of
the embryo at the two-cell stage using a Nanoject II injector
(Drummand Scientiﬁc Company). Embryos were then cultured
until stage 10 or stage 30. Once at the required stage, GFP ex-
pression was conﬁrmed in whole embryos using a Leica MZFL III
microscope (Deerﬁeld, IL) and the expressing embryos ﬁxed in
MEMFA (0.1 MOPS, pH 7.4, 22 mM EGTA, 1 mM MgSO4, and 3.7%
formaldehyde) for 2 h at room temperature and where required,
processed for immunoﬂuorescence as described below.
2.5. Immunoﬂuorescence
For antibody staining embryos were embedded in ﬁsh gelatin
as described previously (Chalmers et al., 2003), except tadpole-
stage (stage 30) embryos, which were incubated in 20% sucrose for
2 h, washed several times in PBS and then embedded in 15% ﬁsh
gelatin for freezing. The embryos were cryosectioned and antibody
stained as described (Chalmers et al., 2003). The following anti-
bodies were used: monoclonal anti-γ-tubulin produced in mouse
clone GTU-88 (Sigma; T6557, 1 in 100), polyclonal rabbit anti-ac-
tive caspase 3 (Abcam; ab13847, 1 in 100) rabbit polyclonal anti-
histone H3 phospho S10 (Abcam; ab5168, 1 in 500). The following
secondary antibodies were used: anti-mouse Alexa 568 (A-11004,
Molecular Probes, Eugene, OR); anti-rabbit Alexa 568 (A-11011,
Molecular Probes). All secondary antibodies were used at a 1 in
200 dilution. The nuclear stain, DAPI (Sigma, D9542, 1 mg/mL) wasused at 1 in 1000 dilution. Stained sections were mounted in
Vectasheild (Vector Labroratories, Burlingame, CA) and imaged on
a Zeiss LSM META confocal microscope (Thornwood, NY). GFP
ﬂuorescence was visualised directly without the use of antibody
staining. All ﬂuorescencent images were captured in the linear
range of the confocal to allow quantiﬁcation (see below).
2.6. Quantiﬁcation and statistics
Quantiﬁcation of cells expressing GFP constructs was carried
out by identifying GFP positive cells with a centrosome(s) in the
section being analysed (clear γ-tubulin staining adjacent to the
nucleus). The area and intensity of the centrosomal GFP was then
measured by using the LSM510 Image Browser software (ZEISS)
and the integrated density was calculated by multiplying the area
by the average intensity across the region of interest. The area,
intensity and integrated density of the γ-tubulin, DAPI and nuclear
GFP staining was measured in the same way. The centrosome
number in GFP positive cells was quantiﬁed based on the number
of clear γ-tubulin foci, each cell was classiﬁed as containing 1, 2 or
Z3 centrosomes and each group was displayed as a percentage of
the total GFP positive cells. Quantiﬁcation of mitotic cells (Phos-
pho-H3 positive) or apoptotic cells (active caspase-3) was carried
out by calculating the % of GFP positive cells that were also positive
for the marker of interest.
Means and SDs were calculated and plotted using GraphPad
Prism 6 (San Diego, CA). Statistical analysis was carried out using
One-way Anova tests with Bonferroni post-test corrections,
po0.05 was considered signiﬁcant. Statistical analysis was based
on data from at least three independent experiments and with a
minimum sample size as described in the ﬁgure legends.3. Results
3.1. The coiled coil, but not the RA domain, is required for cen-
trosomal rassf7 localisation
To begin to understand the functional domains within RASSF7
we set out set out to identify those domains which are responsible
for its centrosomal localisation. Wild type rassf7 is predicted to
have an RA and a coiled-coil domain. In addition, there are two
stretches of amino acids that are not predicted to form an iden-
tiﬁable domain by SMART, which we have called the A and B do-
mains (Fig. 1). A series of constructs were generated which code
for truncated versions of rassf7 fused to GFP (Fig. 1) and RNA
synthesised from these plasmids was injected into embryos. The
amount of centrosomal localisation shown by each truncated
protein was then analysed in cells from stage 10 embryos. The
localisation of the truncated proteins was compared to GFP-rassf7
which co-localised with the centrosomal protein γ-tubulin
(Fig. 2AþF). A GFP control which did not show enrichment at the
centrosomes was used as a negative control (Fig. 2BþF). GFP-
rassf7 also showed some nuclear localisation and sometimes some
perinuclear or cortical enrichment. However, this staining is also
seen in cells expressing the GFP control and so is not speciﬁc to the
rassf7 protein.
The analysis of centrosomal localisation was initially performed
with truncations at the N-terminal end of rassf7. The GFP fusion
protein which lacked an RA domain, GFP-rassf7 (AþCCþB),
showed a very similar pattern of localisation to full length GFP-
rassf7, with clear localisation to γ-tubulin containing structures
(Fig. 2CþF). A similar distribution was observed when both the A
domain and the RA domain were removed, GFP-rassf7 (CCþB)
(Fig. 2DþF). Further truncation of rassf7 to remove the coiled-coil
domain (GFP-rassf7B) resulted in a loss of centrosomal localisation
Fig. 2. The coiled-coil, but not the RA domain, is required for centrosomal rassf7 localisation. Embryos were microinjected with RNA at the two-cell stage, cultured until stage 10, ﬁxed,
sectioned and stained with a centrosomal marker (γ-tubulin/red) and a nuclear marker (DAPI/blue). GFP ﬂuorescence is shown in green. (A) GFP-rassf7 (green) co-localised with γ-
tubulin (red) (arrows) as previously shown (Sherwood et al., 2008). GFP-rassf7 showed some nuclear localisation and sometimes some perinuclear or cortical enrichment. However,
this staining is also seen with the GFP control and so is not speciﬁc to the rassf7 protein. (B) GFP negative control, GFP (green) and γ-tubulin (red, arrows). GFP showed nuclear
localisation and some perinuclear or cortical enrichment, but lacked the centrosomal enrichment seen with GFP-rassf7. (C) GFP-rassf7 (AþCCþB) (green) co-localised with γ-tubulin
(red). (D) GFP-rassf7 (CCþB) (green) co-localised with γ-tubulin (red). (E) GFP-rassf7 (B) (green) showed reduced co-localisation with γ-tubulin (red). In A-E arrows highlight potential
areas for co-localisation and scale bars¼10 μm. (F) The integrated density of GFP ﬂuorescence at the γ-tubulin foci for the GFP-rassf7 fusion proteins and the positive and negative
controls (GFP-rassf7 and GFP). Integrated density of GFP-rassf7 (B) was similar to negative control. (G) Integrated density of γ-tubulin. Expression of full length or truncated GFP-rassf7
proteins did not affect the integrated density of the γ-tubulin staining. Based on at least three independent experiments, n4100 cells, npo0.05.
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(Fig. 2B). The nuclear localisation, seen with the GFP control and
full length GFP-rassf7, was not lost and the ratio between cen-
trosomal GFP and nuclear GFP was reduced (Supplementary Fig. 1).
This shows that the reduction in centrosomal GFP, seen with GFP-
rassf7 (B), cannot be explained by a reduction in RASSF7 levels.
These results suggest that the coiled coil, but not the RA and A
domains, is required for its centrosomal localisation.
The amount of γ-tubulin staining was also measured following
expression of these proteins. There was no signiﬁcant difference
between cells expressing GFP, GFP-rassf7 and the three truncatedFig. 3. Removal of the B domain led to accumulation of truncated rassf7 at γ-tubulin foci
cell stage, cultured until stage 10, ﬁxed, sectioned and stained with a centrosomal mark
green. (A) GFP-rassf7 (RAþAþCC) (green) co-localised with γ-tubulin (red). There appea
nuclear localisation seen with the wildtype construct and the GFP control was also reduc
the protein still showed the nuclear localisation seen with full length rassf7 and the GFP c
but did still show the nuclear localisation seen with the wildtype construct and the GFP
bars¼10 μm. (D) Integrated density of GFP ﬂuorescence at the γ-tubulin foci. GFP-rassf7
(E) Integrated density of the γ-tubulin spot. Cells expressing GFP-rassf7 (RAþAþCC) sh
rassf7. Based on at least three independent experiments, n4100 cells, npo0.05.proteins analysed (Fig. 2G), so expression of these constructs did
not lead to signiﬁcant changes in γ-tubulin staining.
3.2. Removal of the B domain led to accumulation of truncated rassf7
at the centrosomes and increased levels of γ-tubulin staining
Having studied N-terminal truncations, we next investigated
truncations at the C-terminal end of rassf7. Removal of the B do-
main, GFP-rassf7 (RAþAþCC), did not disrupt the ability of the
protein to localise at the centrosome (Fig. 3A), in fact there was a
striking increase in GFP signal that overlapped with the γ-tubulinand increased γ-tubulin staining. Embryos were microinjected with RNA at the two-
er (γ-tubulin/red) and a nuclear marker (DAPI/blue). GFP ﬂuorescence is shown in
red to be increased localisation and also enlargement of the γ-tubulin staining. The
ed. (B) GFP-rassf7 (RAþA) showed reduced co-localisation with γ-tubulin (red), but
ontrol. (C) GFP-rassf7 (RA) (green) did not show co-localisation with γ-tubulin (red),
control. In panels A–C arrows highlight potential areas for co-localisation and scale
(RAþAþCC) showed an increased integrated density when compared to wild type.
owed an increased integrated density when compared to cell expressing wild type
Fig. 4. Mutations in the coiled coil domain reduced the centrosomal localisation of GFP-rassf7. Constructs were made that contained mutations in the coiled-coil region,
embryos were then microinjected, with RNA made from these constructs, at the two-cell stage, cultured until (stage 10), ﬁxed, sectioned and stained with a centrosome
marker (γ-tubulin/red) and a nuclear marker (DAPI/blue). GFP ﬂuorescence is shown in green. (A) The predicted structure of the coiled-coil domain mutations; GFP-rassf7
(WT), GFP-rassf7 (RAþAþCC′þB) with one point mutation, GFP-rassf7 (RAþAþCC″þB) with two point mutations and GFP-rassf7 (RAþAþCC‴þB) with three point
mutations. (B) GFP-rassf7 (RAþAþCC′þB) (green) co-localised with γ-tubulin (red). (C) GFP-rassf7 (RAþAþCC″þB) (green) co-localised with γ-tubulin (red). (D) GFP-rassf7
(RAþAþCC‴þB) (green) showed decreased co-localisation with γ-tubulin (red). In panels A–C arrows highlight potential areas for co-localisation. All three mutant proteins
showed the nuclear localisation seen with the wildtype construct and the GFP control. Scale bars¼10 μm. (E) Integrated density of the GFP ﬂuorescence at the γ-tubulin foci.
GFP-rassf7 (RAþAþCC‴þB) showed reduced centrosomal localisation when compared to the wild type protein. (F) Integrated density of the γ-tubulin spot. Mutations did
not affect the integrated density of the γ-tubulin staining. Based on at least three independent experiments, n4100 cells, npo0.05.
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GFP containing punctae in wholemount embryos (Supplementary
Fig. 2C). Quantiﬁcation revealed that there was a greater than ﬁ-
vefold increase in the amount of GFP that overlapped with the γ-
tubulin containing puncta (Fig. 3D). In contrast GFP localisation in
the nucleus was reduced and the ratio between centrosomal GFPFig. 5. The coiled-coil domain is sufﬁcient for the centrosomal localisation of rassf7. Em
ﬁxed, sectioned and stained with a centrosomal marker (γ-tubulin/red) and a nuclear ma
co-localised with γ-tubulin (red). Accumulation at the centrosome and enlargement of
construct and the GFP control was also reduced. (B) GFP-rassf7 (CC) (green) co-localised w
and the GFP control. (C) GFP-rassf7 (A) (green) did not show co-localisation with γ-tubu
rassf7 and the GFP control. In panels A–C arrows highlight potential areas for co-localisa
GFP-rassf7 (AþCC) showed a signiﬁcantly increased integrated density compared to wild
similar to the GFP negative control. (E) Integrated density of the γ-tubulin foci. GFP-rassf7
to the wild type rassf7. The other constructs did not affect the integrated density of γ-tand nuclear GFP was greatly increased (Supplementary Fig. 1).
Therefore, the increase in centrosomal rassf7 cannot be explained
by an increase in RASSF7 levels. Surprisingly, cells expressing GFP-
rassf7 (RAþAþCC) also had a fourfold increase in the amount of
γ-tubulin staining in comparison to controls (Fig. 3AþE), sug-
gesting that expression of this truncated version of rassf7 canbryos were microinjected with RNA at the two-cell stage, cultured until stage 10,
rker (DAPI/blue). GFP ﬂuorescence is shown in green. (A) GFP-rassf7 (AþCC) (green)
γ-tubulin staining was observed. The nuclear localisation seen with the wildtype
ith γ-tubulin (red) and showed the nuclear localisation seen with full length rassf7
lin (red), but the protein still showed the nuclear localisation seen with full length
tion and scale bars¼10 μm. (D) Integrated density of the GFP at the γ-tubulin foci.
type rassf7. GFP-rassf7 (CC) was similar to wild type rassf7 and GFP-rassf7 (A) was
(AþCC) showed an increase in the integrated density of γ-tubulin when compared
ubulin. Based on at least three independent experiments, n4100 cells, npo0.05.
Table 1
The ability of truncated rassf7 proteins to localise at the centrosome and promote
increased γ-tubulin staining.
GFP domain construct Centrosomal
localisation
Increased γ-tubulin
staining
GFP-RASSF7 (WT) ✓ ✗
GFP-RASSF7 (RAþAþCC) ✓ ✓
GFP-RASSF7 (RAþA) ✗ ✗
GFP-RASSF7 (RA) ✗ ✗
GFP-RASSF7 (AþCCþB) ✓ ✗
GFP-RASSF7 (CCþB) ✓ ✗
GFP-RASSF7 (AþCC) ✓ ✓
GFP-RASSF7 (CC) ✓ ✗
GFP-RASSF7 (A) ✗ ✗
GFP-RASSF7 (B) ✗ ✗
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Removal of the coiled-coil domain and the B domain, GFP-
rassf7 (RAþA), caused a loss of co-localisation with γ-tubulin
(Fig. 3BþD), consistent with the coiled-coil domain being required
for centrosomal rassf7 localisation. The RA domain on its own,
GFP-rassf7 (RA), also failed to co-localise with γ-tubulin
(Fig. 3CþD). In both cases a reduction in the ratio between cen-
trosomal GFP and nuclear GFP was also observed (Supplementary
Fig. 1) and following expression of these two constructs, GFP-
rassf7 (RAþA) and GFP-rassf7 (A), there was no effect on γ-tubulin
staining levels (Fig. 3E).
To further assess the requirement of the coiled coil for locali-
sation a series of point mutations were made which replace hy-
drophobic amino acids with prolines. These are predicted to dis-
rupt the three dimensional architecture of the coiled coil (Fig. 4A).
The triple mutation, which is predicted to cause almost complete
loss of coiled coil structure, showed signiﬁcantly less centrosomal
localisation than wildtype rassf7 (Fig. 4DþE), consistent with the
coiled-coil domain being required for the localisation of rassf7.
Expression of these mutations did not affect the gamma tubulin
staining (Fig. 4F).
3.3. The coiled-coil domain is sufﬁcient for centrosomal rassf7
localisation
The ﬁnal set of constructs to be investigated allowed expression
of the internal domains of rassf7. GFP-rassf7 (AþCC) lacks the
N-terminal RA domain and the C-terminal B domain, but was still
able to localise to the centrosomes (Fig. 5A). Similar to rassf7
which lacked just the B-domain, there was also an increase in GFP
that overlapped with the γ-tubulin, more γ-tubulin staining
(Fig. 5DþE) and an increase in the ratio between centrosomal GFP
and nuclear GFP (Supplementary Fig. 1).
The coiled-coil of rassf7 alone, GFP-rassf7 (CC), was able to
localise to centrosomes (Fig. 5B) at a level comparable to full
length GFP-rassf7 (Fig. 5BþD). This shows that the coiled-coil
domain is sufﬁcient for centrosomal rassf7 localisation, building
on observations described above showing the coiled-coil is re-
quired to localise rassf7 at the centrosome. Expression of the
coiled-coil of rassf7 did not result in increased γ-tubulin signal
(Fig. 5BþE). This argues that the combination of coiled-coil and
the A domain are required for the aberrant accumulation at cen-
trosomes of both rassf7 and γ-tubulin. The ﬁnal truncated protein
to be expressed was GFP-rassf7 (A), which failed to localise to the
centrosomes (Fig. 5CþD) and showed a reduction in the ratio
between centrosomal GFP and nuclear GFP (Supplementary Fig. 1).
It did not have any effect on centrosomal morphology (Fig. 4CþE).
The results from all constructs are summarised in Table 1. The
key ﬁndings are that the coiled-coil domain is sufﬁcient and re-
quired for centrosomal rassf7 localisation. In contrast, the RA do-
main does not seem to be responsible for rassf7's centrosomal
localisation. Constructs which lacked the B domain, but contained
the A domain and the coiled-coil, showed aberrant accumulation
at the centrosomes and resulted in an abnormal increase of γ-
tubulin staining at centrosomal punctae.
3.4. GFP-rassf7 (RAþAþCC) promoted ampliﬁcation of the γ-tubulin
foci and increased numbers of mitotic cells
To investigate the aberrant centrosomal morphology observed
in cells expressing C-terminally truncated rassf7 in more detail, an
analysis of the number of γ-tubulin foci per cell was carried out.
Cells expressing GFP or wild-type GFP-rassf7 had one or two γ-
tubulin foci depending on their cell cycle stage (Fig. 6AþBþD).
However, in cells expressing GFP-rassf7 (RAþAþCC) there were
often three or more γ-tubulin foci (Fig. 6CþD).Given these apparent abnormalities in the centrosomes (in-
creased size and number of γ-tubulin foci) we investigated the
functional consequences of these defects by quantifying the pro-
portion of cells in mitosis. This was achieved by staining for
Phospho-H3 (Fig. 7). GFP-rassf7 (RAþAþCC) expressing cells had
more Phospho-H3 positive cells than cells expressing GFP or GFP-
rassf7 (Fig. 7D). We hypothesise that the centrosomal abnormal-
ities caused by expression of GFP-rassf7 (RAþAþCC) lead to a
delay in progression through mitosis and an accumulation of mi-
totic cells.
3.5. GFP-rassf7 (RAþAþCC) injected embryos showed increased
embryo and cell death
To establish whether embryos which express GFP-rassf7
(RAþAþCC) can survive we cultured injected embryos and
monitored rates of embryo death. Uninjected, GFP injected and
GFP-rassf7 injected embryos showed some death during devel-
opment (Fig. 8A). However, the rate of embryo death was sig-
niﬁcantly increased in embryos injected with GFP-rassf7
(RAþAþCC) (Fig. 8A).
Some stage 30 embryos expressing GFP-rassf7 (RAþAþCC) did
survive (Fig. 8AþB), allowing us to study the subcellular locali-
sation of rassf7 at this stage. GFP and GFP-rassf7 in stage 30 em-
bryos showed similar sub-cellular distributions to stage 10, with
cytoplasmic and centrosomal localisation respectively (Fig. 8CþD).
However, GFP-rassf7 (RAþAþCC) did not co-localise with γ-tu-
bulin in stage 30 embryos (Fig. 8E). Where the GFP-rassf7
(RAþAþCC) was expressed the cells did not appear to have clear
γ-tubulin foci, and where γ-tubulin foci were observed there did
not appear to be expression of the GFP fusion protein. This led to
the question of whether there was increased programmed cell
death associated with this apparent loss of γ-tubulin containing
punctae.
Apoptotic cells in stage 30 embryos were identiﬁed by staining
for active caspase-3 (Fig. 9). GFP and GFP-rassf7 expressing control
cells showed low levels of active caspase-3 staining
(Fig. 9AþBþD). In contrast, a high percentage of GFP-rassf7
(RAþAþCC) expressing cells were positive for active caspase-3
(Fig. 9CþD). This data suggests that early centrosome defects may
lead to later centrosome loss and apoptosis.
3.6. Mutating the coiled coil of GFP-rassf7 (RAþAþCC) reduces its
ability to promote centrosomal defects
Expression of GFP-rassf7 (RAþAþCC) caused early cen-
trosomal defects and later cell and embryo death. A key question is
whether these defects are mediated by truncated rassf7 at the
centrosome or in other cellular compartments, for example the
Fig. 6. Expression of GFP-rassf7 (RAþAþCC) caused increased numbers of γ-tubulin foci. Embryos were microinjected with RNA at the two-cell stage, cultured until stage
10, ﬁxed, sectioned and stained with a centrosomal marker (γ-tubulin/red) and a nuclear marker (DAPI/blue). GFP ﬂuorescence is shown in green. (A) GFP (green) and γ-
tubulin (red). (B) GFP-rassf7 (green) and γ-tubulin (red). (C) GFP-rassf7 (RAþAþCC) (green) and γ-tubulin (red). Cells expressing GFP-rassf7 (RAþAþCC) showed increased
numbers of γ-tubulin foci. In A–C arrows highlight example cells and scale bars¼10 μm. (D) Centrosome number for GFP, GFP-rassf7 and GFP-rassf7 (RAþCþCC) injected
cells. Unlike controls, GFP-rassf7 (RAþAþCC) injected cells frequently had more than two γ-tubulin foci. Based on at least three independent experiments, n4100 cells.
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mutations, which showed reduced centrosomal localisation
(Fig. 4), in the GFP-rassf7 (RAþAþCC) construct (Fig. 10A). This
would produce a protein with the same truncation but with re-
duced ability to bind the centrosome and so show if loss of cen-
trosomal localisation would reduce the centrosomal defects and
cell death seen previously.
The GFP-rassf7 (RAþAþCC‴) protein showed less centrosomal
localisation than either the wildtype RASSF7 or the truncated GFP-rassf7 (RAþAþCC), which accumulates at the centrosome
(Fig. 10B–D). Unexpectedly the mutated and truncated construct
showed a distinctive punctate nuclear localisation (Fig. 10D),
which was not observed with the other constructs.
Cell expressing GFP-rassf7 (RAþAþCC‴) showed reduced
centrosomal defects when compared to GFP-rassf7 (RAþAþCC)
positive cells, they did not have enlarged centrosomes (Fig. 10D) or
duplicated centrosomes (Fig. 10E). This suggests that the early
centrosome defects require the increased centrosomal localisation
Fig. 7. GFP-rassf7 (RAþAþCC) injected cells accumulate in mitosis. Embryos were microinjected with RNA at the two-cell stage, cultured until stage 10, ﬁxed, sectioned and
stained with a mitosis marker (Phospho-H3/red) and a nuclear marker (DAPI/blue). GFP ﬂuorescence is shown in green. (A) GFP (green) injected cells were stained for
Phospho-H3 (red). (B) GFP-rassf7 (green) injected cells were stained for Phospho-H3 (red). (C) GFP-rassf7 (RAþAþCC) (green) injected cells were stained for Phospho-H3
(red). The number of Phospho-H3 positive cells increased when compared to GFP and GFP-rassf7 expressing cells. In panels A–C arrows highlight example nuclear regions
and all bars¼10 μm. (D) The percentage of GFP positive cells that are Phospho-H3 positive. Based on at least three independent experiments, n4100 cells, npo0.05.
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GFP-rassf7 (RAþAþCC‴) did show increased amounts of cell
death, comparable to that seen in cells expressing GFP-rassf7
(RAþAþCC) (Supplementary Fig. 3). The death seen with GFP-
rassf7 (RAþAþCC‴) might mean that cell death is not linked to
the centrosomal localisation of this truncated protein, but it might
also be that the extra nuclear localisation seen with this construct
promotes death by an alternative route. Therefore, it is not cur-
rently possible to say if the cell death requires the centrosomal
localisation seen with GFP-rassf7 (RAþAþCC).3.7. Analysis of RASSF7 mutations in human cancers
Truncated rassf7 which lacks its B-domain can drive centro-
some abnormalities (enlarged and increased numbers of γ-tubulin
foci), something which is often seen in cancer cells. This prompted
us to investigate whether mutations might produce similar trun-
cations of RASSF7 in human cancer samples.
The cBioPortal database was used to search sequence data from
over eighty different cancer studies and more than 20,000 patient
samples (Fig. 11A). RASSF7 was found to be ampliﬁed in a number
of tumours, consistent with previous reports of increased RASSF7
Fig. 8. GFP-rassf7 injected embryos at tadpole stages. Embryos were microinjected with RNA at the two-cell stage, cultured until tadpole stages (stage 30), ﬁxed, sectioned
and stained with a centrosomal marker (γ-tubulin/red) and a nuclear marker (DAPI/blue). GFP ﬂuorescence is shown in green. (A) Embryo survival for uninjected, GFP
injected, GFP-rassf7 injected and GFP-rassf7 (RAþAþCC) injected embryos. Based on at least three independent experiment, n460 embryos. (B) Wholemount stage 30
embryos expressing GFP, GFP-rassf7 and GFP-rassf7 (RAþAþCC). (C) GFP (green) expressing cells stained with γ-tubulin (red) from stage 30 embryos. (D) GFP-rassf7 (green)
expressing cells stained with γ-tubulin (red) from stage 30 embryos. (E) GFP-rassf7 (RAþAþCC) (green) expressing cells stained with γ-tubulin (red) at stage 30. Unlike the
situation at stage 10, the GFP-rassf7 (RAþAþCC) ﬂuorescence (green) did not co-localise with γ-tubulin (red) and γ-tubulin foci appeared to have been lost from GFP-rassf7
(RAþAþCC) expressing cells. In panels C–E arrows highlight possible regions where co-localisation might occur and all scale bars¼10 μm.
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were also identiﬁed (Fig. 11B). The mutations were mainly mis-
sense mutations, but there were two nonsense mutations and one
deletion that would be predicted to truncate RASSF7 (Fig. 11B).
Two of the nonsense mutations are predicted to produce proteins
that are truncated in or near the RA domain (Fig. 11B2þ3). Our
data suggests that these are unlikely to localise to the centrosome
and may be hypomorphs. The nonsense mutation which is at R285
would be predicted to produce a protein that would be truncated
at the end of the coiled-coil (Fig. 11B1). This resembles GFP-rassf7
(RAþAþCC) (Fig. 1), and raises the possibility that in this cancer
truncated RASSF7 might have accumulated at the centrosome anddriven centrosome defects.4. Discussion
RASSF7 is a key regulator of mitosis and possible oncogene, but
the molecular basis of its function remains to be elucidated. Here,
we show that the coiled coil domain is sufﬁcient and required for
its centrosomal localisation. In contrast, the RA domain of rassf7
does not appear to play a key role in mediating its localisation.
Removing the B domain of RASSF7 caused it to accumulate at γ-
tubulin foci and cause accumulation of abnormally high levels of
Fig. 9. GFP-rassf7 (RAþAþCC) injected cells undergo increased rates of apoptosis. Embryos were microinjected with RNA at the two-cell stage, cultured until tadpole stages
(stage 30), ﬁxed, sectioned and stained with an apoptosis marker (Active caspase-3/red) and a nuclear marker (DAPI/blue). GFP ﬂuorescence is shown in green. (A) GFP
injected cells (green) were stained with an antibody against active caspase-3 (red). (B) GFP-rassf7 injected cells (green) were stained with an antibody against active caspase-
3 (red). (C) GFP-rassf7 (RAþAþCC) injected cells (green) were stained an antibody against active caspase-3 (red). These cells showed increased levels of active caspase-3
(red) positive nuclei compared to controls. In panels A–C arrows highlight GFP positive cells. All bars¼10 μm. (D) The % percentage of GFP positive cells which were active
caspase-3 positive (Based on at least three independent experiments, n4100 cells, npo0.05).
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number of γ-tubulin foci per cell, elevated the number of cells in
mitosis by a process which appears to require the protein to lo-
calise at the centrosome. Ultimately expression of truncated rassf7
resulted in cell and embryo death. Finally, analysis of sequences
from human tumours identiﬁed a similar truncated version of
RASSF7 from a clear renal cell carcinoma, suggesting that RASSF7
may promote centrosome defects and act as an oncogene in asmall subset of tumours with such mutations.
Our data show that the coiled coil domain is key in driving the
localisation of rassf7 to the centrosome. Previous proteomic
characterisation of centrosomes found that a high percentage of
centrosomal proteins contain a coiled-coil (Andersen et al., 2003)
and many centrosome proteins with coiled-coils have been stu-
died. These include, pericentrin (Doxsey et al., 1994), Ninein
(Bouckson Castaing et al., 1996), Hice1 (Wu et al., 2008), TACC
Fig. 10. Mutating the coiled coil domain reduced the centrosomal defects seen in cells expressing GFP-rassf7 (RAþAþCC). Embryos were microinjected with RNA at the two-
cell stage, cultured until stage 10, ﬁxed, sectioned and stained with a centrosomal marker (γ-tubulin/red) and a nuclear marker (DAPI/blue). GFP ﬂuorescence is shown in
green. (A) Predicted structure of GFP-rassf7 (RAþAþCC‴) which lacks the B domain and has been mutated at three sites to disrupt the coiled coil. (B) GFP-rassf7 (green) co-
localised with γ-tubulin (red). (C) GFP-rassf7 (RAþAþCC) (green) co-localised with γ-tubulin (red). Accumulation at the centrosome and enlargement of γ-tubulin staining
was also seen. (D) GFP-rassf7 (RAþAþCC‴) (green) did not co-localise with γ-tubulin (red), but accumulated as distinct puncta within the nucleus. Enlargement of γ-tubulin
staining was not seen. In panels B–D arrows highlight the potential area for co-localisation and scale bars¼10 μm. (E) Centrosome number for GFP, GFP-rassf7, GFP-rassf7
(RAþCþCC) and GFP-rassf7 (RAþCþCC‴) injected cells. GFP-rassf7 (RAþCþCC‴) injected cells did not have the additional γ-tubulin foci frequently seen in GFP-rassf7
(RAþAþCC) injected cells. Based on at least three independent experiments, n4100 cells.
T. Gulsen et al. / Developmental Biology 409 (2016) 502–517514(Gergely et al., 2000a, b), Centriolin (Gromley et al., 2003), Cep135
(Gromley et al., 2003), C-Nap1 (Fry et al., 1998) and Pix1/2 (Hames
et al., 2008). Previous work has also shown that coiled coil do-
mains can mediate centrosome localisation. For example, TACCproteins have a C-terminal coiled-coil domain which is required
for interactions with the centrosomes (Gergely et al., 2000b).
Therefore, our results with the coiled-coil of rassf7 support the
idea that coiled-coils are required for the localisation of a number
Fig. 11. RASSF7 mutations in human cancer samples. (A) Alterations in RASSF7 were identiﬁed in cancer studies using the cBioPortal for cancer genomics website which
contained data from 89 cancer genomic studies covering a total of 20,958 tumour samples. (B) Mutations in the RASSF7 (red: nonsense mutations or deletions, green:
missense mutations). The predicted structure of RASSF7 for the three nonsense mutations. Mutations 1, R285n. Mutation 2, S97n. Mutation 3, Q63fs. The predicted structure
of the R285n mutation reassembles that of GFP-rassf7 (RAþAþCC).
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The other domains of rassf7 did not appear to be required for
its centrosomal localisation. These included the RA domain, mak-
ing it likely that the role of this domain is to interact with effector
molecules, potentially recruiting them to the centrosome where
they may regulate mitosis. RASSF7 has been shown to bind NRas
(Takahashi et al., 2011), HRas and KRas (Chan et al., 2013) in pull
down experiments with tagged proteins, although it remains to be
conﬁrmed that RASSF7 is binding endogenous Ras family mem-
bers. Recent proteomic studies have shown that RASSF7 can in-
teract with a number of other cellular proteins, including ASPP and
PP1 family members (Hauri et al., 2013). dRASSF8, the Drosophila
homologue of RASSF7 and RASSF8, can also bind dASPP although
dRASSF8 protein localises at epithelial junctions rather than the
centrosomes (Langton et al., 2009). Future work will need to es-
tablish if the RA, and also the A domain, are bringing these or
other potential effectors to the centrosomes to regulate mitosis.Removing the B domain of rassf7 had a striking effect on its
localisation, with a far greater amount of rassf7 colocalising with
γ-tubulin. There are a number of possible models to explain this
result. The B domain might act as an auto-inhibitory domain that
binds to the coiled coil of rassf7 in a regulated way and while in a
closed conformation blocks the coiled coil from binding cen-
trosomal proteins. Removing the B domain could then cause un-
regulated accumulation of rassf7 at the centrosome. Another
possibility is that the B domain acts to control the turnover of
rassf7 at centrosomes in some way and there are predicted
phosphorylation sites for a number of mitotic kinases in the B
domain that could potentially regulate rassf7 turnover. Finally,
increased localisation could be driven by loss of nuclear localisa-
tion making more rassf7 available for centrosome binding or
greater delivery to the centrosome, perhaps, by microtubules.
The expression of RASSF7 has been shown to be increased in a
number of tumour types (Friess et al., 2003; Li et al., 2013;
T. Gulsen et al. / Developmental Biology 409 (2016) 502–517516Logsdon et al., 2003; Lowe et al., 2007; Tan et al., 2009), but it is
not clear if RASSF7 can act as an oncogene and promote tumour
formation. Our previous work shows that overexpression of
wildtype RASSF7, carried out for localisation and rescue experi-
ments, did not have a clear effect on HeLa cells or Xenopus em-
bryos (Recino et al., 2010; Sherwood et al., 2008). In our current
study expressing tagged full length rassf7 did not drive alterations
in centrosome size, number, mitotic cells or cell death. This sug-
gests that increased wild type RASSF7 may not act in an oncogenic
role, although RASSF7 can also protect against stress induced cell
death, an aspect that we have not investigated here (Takahashi
et al., 2011). In contrast to the wildtype protein, expression of
truncated rassf7 which lacked the B domain caused elevated
amounts of γ-tubulin staining at foci and an increased number of
γ-tubulin foci per cell. This phenotype resemble the enlargement
and ampliﬁcation of centrosomes that can occur in cancer cells
(Godinho and Pellman, 2014; Nigg, 2006) and recent evidence
suggests that centrosome ampliﬁcation can drive cellular invasion
(Godinho et al., 2014). Interestingly, we found a mutation in
RASSF7 from a renal clear cell carcinoma that would produce a
similar truncation. Our data suggests the protein produced fol-
lowing this mutation could drive centrosome defects, which
would be consistent with RASSF7 acting as an oncogene in this
tumour. This oncogenic role would require the cancer cells to also
have defects in apoptosis as the truncated protein also promoted
cell death which could counter a role in promoting tumour for-
mation. We have currently found one tumour with this type of
mutation, from a database containing sequences from 80 studies
and over 20,000 patient samples, suggesting that it may only be a
small subset of tumours where mutated RASSF7 functions in this
way. However, as sequences frommore and more tumours become
available it will be interesting to see whether additional tumours
with C-terminal RASSF7 truncations are discovered.Acknowledgements
TG's work was supported by the Turkish Government PhD
studentship programme. We would like to thank Benjamin Sharpe
for his help with images and comments on the manuscript. All
other members of ADC, PRW, Will Wood, Julien Licchesi and Jim
Caunt labs are thanked for helpful comments and support
throughout the project. The confocal analysis was carried out in
the University of Bath Bioimaging Suite and we thank Dr. Adrian
Rogers for his help and advice. AC, PRW and TG are members of
the Cancer Research @ Bath network.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx. doi.org/10.1016/j.ydbio.2015.11.001.References
Andersen, J.S., Wilkinson, C.J., Mayor, T., Mortensen, P., Nigg, E.A., Mann, M., 2003.
Proteomic characterization of the human centrosome by protein correlation
proﬁling. Nature 426, 570–574.
Bartlett, H.L., Weeks, D.L., 2008. Lessons from the lily pad: using Xenopus to un-
derstand heart disease. Drug Discov. Today: Dis. Model. 5, 141–146.
Basto, R., Pines, J., 2007. The centrosome opens the way to mitosis. Dev. Cell 12,
475–477.
Bouckson Castaing, V., Moudjou, M., Ferguson, D.J.P., Mucklow, S., Belkaid, Y., Milon,
G., Crocker, P.R., 1996. Molecular characterisation of ninein, a new coiled-coil
protein of the centrosome. J. Cell Sci. 109, 179–190.
Boveri, Th., 1902. Mehrpolige Mitosen als Mittel zur Analyse des Zellkerns. Verh. d.
Phys. Med. Ges. zu Wurzburg, vol. XXXV.Camps, C., Buffa, F.M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., Harris, A.L.,
Gleadle, J.M., Ragoussis, J., 2008. hsa-miR-210 is induced by hypoxia and is an
independent prognostic factor in breast cancer. Clin. Cancer Res. 14, 1340–1348.
Chalmers, A.D., Lacham, K., Shin, Y., Sherwood, V., Cho, K.W.Y., Papalopulu, N., 2006.
Grainyhead-like 3, a transcription factor identiﬁed in a microarray screen,
promotes the speciﬁcation of the superﬁcial layer of the embryonic epidermis.
Mech. Dev. 123, 702–718.
Chalmers, A.D., Pambos, M., Mason, J., Lang, S., Wylie, C., Papalopulu, N., 2005. aPKC,
Crumbs3 and Lgl2 control apicobasal polarity in early vertebrate development.
Development 132, 977–986.
Chalmers, A.D., Strauss, B., Papalopulu, N., 2003. Oriented cell divisions asymme-
trically segregate aPKC and generate cell fate diversity in the early Xenopus
embryo. Development 130, 2657–2668.
Chan, J.J., Flatters, D., Rodrigues-Lima, F., Yan, J., Thalassinos, K., Katan, M., 2013.
Comparative Analysis of Interactions of RASSF1-10. Advances in Biological
Regulation 53, 190–201.
Conlon, F.L., Miteva, Y., Kaltenbrun, E., Waldron, L., Greco, T.M., Cristea, I.M., 2012.
Immunoisolation of protein complexes from Xenopus. Methods Mol. Biol. 917,
369–390.
de Carcer, G., Malumbres, M., 2014. A centrosomal route for cancer genome in-
stability. Nat. Cell. Biol. 16, 504–506.
Doxsey, S.J., Stein, P., Evans, L., Calarco, P.D., Kirschner, M., 1994. Pericentrin, a
highly conserved centrosome protein involved in microtubule organization.
Cell 76, 639–650.
Friess, H., Ding, J., Kleeff, J., Fenkell, L., Rosinski, J.A., Guweidhi, A., Reidhaar-Olson, J.
F., Korc, M., Hammer, J., Buchler, M.W., 2003. Microarray-based identiﬁcation of
differentially expressed growth- and metastasis-associated genes in pancreatic
cancer. Cell. Mol. Life Sci. 60, 1180–1199.
Fry, A.M., Mayor, T., Meraldi, P., Stierhof, Y.D., Tanaka, K., Nigg, E.A., 1998. C-Nap1, a
novel centrosomal coiled-coil protein and candidate substrate of the cell cycle-
regulated protein kinase Nek2. J. Cell Biol. 141, 1563–1574.
Gergely, F., Karlsson, C., Still, I., Cowell, J., Kilmartin, J., Raff, J.W., 2000a. The TACC
domain identiﬁes a family of centrosomal proteins that can interact with mi-
crotubules. Proc. Natl. Acad. Sci. USA 97, 14352–14357.
Gergely, F., Kidd, D., Jeffers, K., Wakeﬁeld, J.G., Raff, J.W., 2000b. D-TACC: a novel
centrosomal protein required for normal spindle function in the early Droso-
phila embryo. Embo J. 19, 241–252.
Godinho, S.A., Pellman, D., 2014. Causes and consequences of centrosome ab-
normalities in cancer. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 369.
Godinho, S.A., Picone, R., Burute, M., Dagher, R., Su, Y., Leung, C.T., Polyak, K., Brugge,
J.S., Thery, M., Pellman, D., 2014. Oncogene-like induction of cellular invasion
from centrosome ampliﬁcation. Nature 510, 167.
Gromley, A., Jurczyk, A., Sillibourne, J., Halilovic, E., Mogensen, M., Groisman, I.,
Blomberg, M., Doxsey, S., 2003. A novel human protein of the maternal cen-
triole is required for the ﬁnal stages of cytokinesis and entry into S phase. J. Cell
Biol. 161, 535–545.
Hames, R.S., Hames, R., Prosser, S.L., Euteneuer, U., Lopes, C.A.M., Moore, W.,
Woodland, H.R., Fry, A.M., 2008. Pix1 and Pix2 are novel WD40 microtubule-
associated proteins that colocalize with mitochondria in Xenopus germ plasm
and centrosomes in human cells. Exp. Cell Res. 314, 574–589.
Hauri, S., Wepf, A., van Drogen, A., Varjosalo, M., Tapon, N., Aebersold, R., Gstaiger,
M., 2013. Interaction proteome of human Hippo signaling: modular control of
the co-activator YAP1. Mol. Syst. Biol. 9 (713), 1–16.
Hesson, L.B., Dunwell, T.L., Cooper, W.N., Catchpoole, D., Brini, A.T., Chiaramonte, R.,
Grifﬁths, M., Chalmers, A.D., Maher, E.R., Latif, F., 2009. The novel RASSF6 and
RASSF10 candidate tumour suppressor genes are frequently epigenetically in-
activated in childhood leukaemias. Mol. Cancer 8, 1–10.
Langton, P.F., Colombani, J., Chan, E.H.Y., Wepf, A., Gstaiger, M., Tapon, N., 2009. The
dASPP-dRASSF8 complex regulates cell–cell adhesion during drosophila retinal
morphogenesis. Curr. Biol. 19, 1969–1978.
Lee, C.-M., Yang, P., Chen, L.-C., Chen, C.-C., Wu, S.-C., Cheng, H.-Y., Chang, Y.-S., 2011.
A novel role of RASSF9 in maintaining epidermal homeostasis. PLoS One 6 (3),
1–21.
Li, X., Zhao, G., Wang, Y., Zhang, J., Duan, Z., Xin, S., 2013. RASSF7 and RASSF8
proteins are predictive factors for development and metastasis in malignant
thyroid neoplasms. J. Cancer Res. Ther. 9, S173–S177.
Liang, G.-P., Su, Y.-Y., Chen, J., Yang, Z.-C., Liu, Y.-S., Luo, X.-D., 2009. Analysis of the
early adaptive response of endothelial cells to hypoxia via a long serial analysis
of gene expression. Biochem. Biophys. Res. Commun. 384, 415–419.
Lock, F.E., Underhill-Day, N., Dunwell, T., Matallanas, D., Cooper, W., Hesson, L.,
Recino, A., Ward, A., Pavlova, T., Zabarovsky, E., Grant, M.M., Maher, E.R.,
Chalmers, A.D., Kolch, W., Latif, F., 2010. The RASSF8 candidate tumor sup-
pressor inhibits cell growth and regulates the Wnt and NF-kappa B signaling
pathways. Oncogene 29, 4307–4316.
Logsdon, C.D., Simeone, D.M., Binkley, C., Arumugam, T., Greenson, J.K., Giordano, T.
J., Misek, D.E., Kuick, R., Hanash, S., 2003. Molecular proﬁling of pancreatic
adenocarcinoma and chronic pancreatitis identiﬁes multiple genes differen-
tially regulated in pancreatic cancer (vol. 63, pg 2649, 2003). Cancer Res. 63,
3445.
Lowe, A.W., Olsen, M., Hao, Y., Lee, S.P., Lee, K.T., Chen, X., van de Rijn, M., Brown, P.
O., 2007. Gene expression patterns in pancreatic tumors, cells and tissues. PLoS
One 2 (3), 1–11.
Luders, J., Stearns, T., 2007. Opinion-microtubule-organizing centres: a re-evalua-
tion. Nat. Rev. Mol. Cell Biol. 8, 161–167.
Nigg, E.A., 2006. Origins and consequences of centrosome aberrations in human
cancers. Int. J. Cancer 119, 2717–2723.
T. Gulsen et al. / Developmental Biology 409 (2016) 502–517 517Nieuwkoop, P.D., Faber, J., 1967. Normal Table of Xenopus laevis. North Holland,
Amsterdam.
Recino, A., Sherwood, V., Flaxman, A., Cooper, W.N., Latif, F., Ward, A., Chalmers, A.
D., 2010. Human RASSF7 regulates the microtubule cytoskeleton and is required
for spindle formation, Aurora B activation and chromosomal congression dur-
ing mitosis. Biochem. J. 430, 207–213.
Richter, A.M., Pfeifer, G.P., Dammann, R.H., 2009. The RASSF proteins in cancer;
from epigenetic silencing to functional characterization. Biochim. Biophys.
Acta – Rev. Cancer 1796, 114–128.
Satinover, D.L., Leach, C.A., Stukenberg, P.T., Brautigan, D.L., 2004. Activation of
Aurora-A kinase by protein phosphatase inhibitor-2, a bifunctional signaling
protein. Proc. Natl. Acad. Sci. USA 101, 8625–8630.
Sherwood, V., Manbodh, R., Sheppard, C., Chalmers, A.D., 2008. RASSF7 is a member
of a new family of RAS association domain-containing proteins and is required
for completing mitosis. Mol. Biol. Cell 19, 1772–1782.
Sherwood, V., Recino, A., Jeffries, A., Ward, A., Chalmers, A.D., 2010. The N-terminal
RASSF family: a new group of Ras-association-domain-containing proteins,
with emerging links to cancer formation. Biochem. J. 425, 303–311.
Sive, H.L., Grainger, R.M., Harland, R.M., 2000. Early development of Xenopus laevis:
a laboratory manual: early development of Xenopus laevis. A Laboratory
Manual, pp. i–ix,1–338.
Takahashi, S., Ebihara, A., Kajiho, H., Kontani, K., Nishina, H., Katada, T., 2011. RASSF7negatively regulates pro-apoptotic JNK signaling by inhibiting the activity of
phosphorylated-MKK7. Cell. Death Differ. 18, 645–655.
Tan, D.S.P., Lambros, M.B.K., Rayter, S., Natrajan, R., Vatcheva, R., Gao, Q., Marchio, C.,
Geyer, F.C., Savage, K., Parry, S., Fenwick, K., Tamber, N., Mackay, A., Dexter, T.,
Jameson, C., McCluggage, W.G., Williams, A., Graham, A., Faratian, D., El-Bah-
rawy, M., Paige, A.J., Gabra, H., Gore, M.E., Zvelebil, M., Lord, C.J., Kaye, S.B.,
Ashworth, A., Reis-Filho, J.S., 2009. PPM1D Is a potential therapeutic target in
ovarian clear cell carcinomas. Clin. Cancer Res. 15, 2269–2280.
Underhill-Day, N., Hill, V., Latif, F., 2011. N-terminal RASSF family (RASSF7-RASSF10)
A mini review. Epigenetics 6, 284–292.
Volodko, N., Gordon, M., Salla, M., Abu Ghazaleh, H., Baksh, S., 2014. RASSF tumor
suppressor gene family: biological functions and regulation. Febs Lett. 588,
2671–2684.
Wang, Y., Ma, T., Bi, J., Song, B., Zhou, Y., Zhang, C., Gao, M., 2014. RASSF10 is epi-
genetically inactivated and induces apoptosis in lung cancer cell lines. Biomed.
Pharmacother. 68, 321–326.
Weitzel, J.N., Kasperczyk, A., Mohan, C., Krontiris, T.G., 1992. The HRAS1 Gene-
Cluster-2 upstream regions recognizing transcripts and a 3rd encoding a gene
with a leucine zipper domain. Genomics 14, 309–319.
Wu, G., Lin, Y.-T., Wei, R., Chen, Y., Shan, Z., Lee, W.-H., 2008. Hice1, a novel mi-
crotubule-associated protein required for maintenance of spindle integrity and
chromosomal stability in human cells. Mol. Cell. Biol. 28, 3652–3662.
